Increased expression of methionine sulfoxide reductases B3 is associated with poor prognosis in gastric cancer

Ma,Xiaoming; Wang,Jian; Zhao,Mingzuo; Huang,Hailong; Wu,Jianqiang

doi:10.3892/ol.2019.10318

Increased expression of methionine sulfoxide reductases B3 is associated with poor prognosis in gastric cancer

Authors:
- Xiaoming Ma
- Jian Wang
- Mingzuo Zhao
- Hailong Huang
- Jianqiang Wu
View Affiliations

Affiliations: Department of Gastrointestinal Surgery, Nanjing Drum Tower Hospital Group Suqian People's Hospital, Xuzhou Medical University, Suqian, Jiangsu 223800, P.R. China
Published online on: May 6, 2019 https://doi.org/10.3892/ol.2019.10318
Pages: 465-471
Copyright: © Ma et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the expression of methionine sulfoxide reductases B3 (MSRB3) in gastric cancer (GC) and its clinical significance. A total of 90 specimens from patients with GC were collected to evaluate MSRB3 protein expression by immunohistochemical staining. The associations between MSRB3 protein expression, clinicopathological characteristics and prognosis of patients with GC were subsequently investigated. The results demonstrated that MSRB3 protein expression in GC tissues samples was significantly higher compared with that in paired adjacent normal tissues (P=0.017). Among the 90 GC cases, 64 (71.1%) exhibited higher MSRB3 expression. In addition, the diagnostic value of MSRB3 for patients with GC was estimated with a sensitivity of 71.1% and a specificity of 46.7%. However, MSRB3 expression was not associated with clinicopathological characteristics of patients with GC. Kaplan‑Meier analysis indicated that patients with high MSRB3 expression had significantly shorter overall survival (OS) times compared with those with low expression (P=0.040). Univariate Cox regression analysis indicated that maximum tumor diameter, depth of invasion, lymph node metastasis, Tumor‑Node‑Metastasis (TNM) stage and MSRB3 expression were significantly associated with OS time. Multivariate Cox regression analysis indicated that MSRB3 was an independent predicting factor for the OS time of patients with GC (P=0.049). In addition, analysis using The Cancer Genome Atlas (TCGA) database validated these results. Kaplan‑Meier analysis revealed that higher MSRB3 mRNA expression was associated with poorer OS time in 442 patients with GC (P=0.004). Univariate analysis of the TCGA data indicated that age, depth of invasion, lymph node metastasis, distant metastasis, TNM stage and MSRB3 expression were significantly associated with OS time; however, sex and histological differentiation were not associated with OS time. Multivariate analysis demonstrated that MSRB3 was an independent prognostic factor in patients with GC (P=0.001). In conclusion, these results demonstrated that MSRB3 expression was upregulated in patients GC, which suggests that MSBR3 may serve as a potential prognostic biomarker.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Shen YH, Xie ZB, Yue AM, Wei QD, Zhao HF, Yin HD, Mai W, Zhong XG and Huang SR: Expression level of microRNA-195 in the serum of patients with gastric cancer and its relationship with the clinicopathological staging of the cancer. Eur Rev Med Pharmacol Sci. 20:1283–1287. 2016.PubMed/NCBI
3	Miao R, Guo X, Zhi Q, Shi Y, Li L, Mao X, Zhang L and Li C: VEZT, a novel putative tumor suppressor, suppresses the growth and tumorigenicity of gastric cancer. PLoS One. 8:e744092013. View Article : Google Scholar : PubMed/NCBI
4	Chen Y, Pan K, Li S, Xia J, Wang W, Chen J, Zhao J, Lü L, Wang D, Pan Q, et al: Decreased expression of V-set and immunoglobulin domain containing 1 (VSIG1) is associated with poor prognosis in primary gastric cancer. J Surg Oncol. 106:286–293. 2012. View Article : Google Scholar : PubMed/NCBI
5	Lee J, Lim DH, Kim S, Park SH, Park JO, Park YS, Lim HY, Choi MG, Sohn TS, Noh JH, et al: Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: The ARTIST trial. J Clin Oncol. 30:268–273. 2012. View Article : Google Scholar : PubMed/NCBI
6	Matés JM, Pérez-Gómez C and Núñez de Castro I: Antioxidant enzymes and human diseases. Clin Biochem. 32:595–603. 1999. View Article : Google Scholar : PubMed/NCBI
7	Krause KH: Aging: A revisited theory based on free radicals generated by NOX family NADPH oxidases. Exp Gerontol. 42:256–262. 2007. View Article : Google Scholar : PubMed/NCBI
8	Valko M, Izakovic M, Mazur M, Rhodes CJ and Telser J: Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem. 266:37–56. 2004. View Article : Google Scholar : PubMed/NCBI
9	Schumacker PT: Reactive oxygen species in cancer cells: Live by the sword, die by the sword. Cancer Cell. 10:175–176. 2006. View Article : Google Scholar : PubMed/NCBI
10	Pelicano H, Carney D and Huang P: ROS stress in cancer cells and therapeutic implications. Drug Resist Updat. 7:97–110. 2004. View Article : Google Scholar : PubMed/NCBI
11	Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M and Telser J: Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 39:44–84. 2007. View Article : Google Scholar : PubMed/NCBI
12	Valko M, Rhodes CJ, Moncol J, Izakovic M and Mazur M: Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact. 160:1–40. 2006. View Article : Google Scholar : PubMed/NCBI
13	Cooke MS, Evans MD, Dizdaroglu M and Lunec J: Oxidative DNA damage: Mechanisms, mutation, and disease. FASEB J. 17:1195–1214. 2003. View Article : Google Scholar : PubMed/NCBI
14	Klaunig JE and Kamendulis LM: The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol. 44:239–267. 2004. View Article : Google Scholar : PubMed/NCBI
15	Halliwell B: Antioxidants in human health and disease. Annu Rev Nutr. 16:33–50. 1996. View Article : Google Scholar : PubMed/NCBI
16	Kim HY and Gladyshev VN: Methionine sulfoxide reductases: Selenoprotein forms and roles in antioxidant protein repair in mammals. Biochem J. 407:321–329. 2007. View Article : Google Scholar : PubMed/NCBI
17	Kwak GH, Kim TH and Kim HY: Down-regulation of MsrB3 induces cancer cell apoptosis through reactive oxygen species production and intrinsic mitochondrial pathway activation. Biochem Biophys Res Commun. 483:468–474. 2017. View Article : Google Scholar : PubMed/NCBI
18	Kim HY: The methionine sulfoxide reduction system: Selenium utilization and methionine sulfoxide reductase enzymes and their functions. Antioxid Redox Signal. 19:958–969. 2013. View Article : Google Scholar : PubMed/NCBI
19	Lim DH, Han JY, Kim JR, Lee YS and Kim HY: Methionine sulfoxide reductase B in the endoplasmic reticulum is critical for stress resistance and aging in Drosophila. Biochem Biophys Res Commun. 419:20–26. 2012. View Article : Google Scholar : PubMed/NCBI
20	Kim HY and Gladyshev VN: Role of structural and functional elements of mouse methionine-S-sulfoxide reductase in its subcellular distribution. Biochemistry. 44:8059–8067. 2005. View Article : Google Scholar : PubMed/NCBI
21	Kim G, Cole NB, Lim JC, Zhao H and Levine RL: Dual sites of protein initiation control the localization and myristoylation of methionine sulfoxide reductase A. J Biol Chem. 285:18085–18094. 2010. View Article : Google Scholar : PubMed/NCBI
22	Vougier S, Mary J and Friguet B: Subcellular localization of methionine sulphoxide reductase A (MsrA): Evidence for mitochondrial and cytosolic isoforms in rat liver cells. Biochem J. 373:531–537. 2003. View Article : Google Scholar : PubMed/NCBI
23	Kim HY and Gladyshev VN: Methionine sulfoxide reduction in mammals: Characterization of methionine-R-sulfoxide reductases. Mol Biol Cell. 15:1055–1064. 2004. View Article : Google Scholar : PubMed/NCBI
24	Kwak GH, Lim DH, Han JY, Lee YS and Kim HY: Methionine sulfoxide reductase B3 protects from endoplasmic reticulum stress in Drosophila and in mammalian cells. Biochem Biophys Res Commun. 420:130–135. 2012. View Article : Google Scholar : PubMed/NCBI
25	Zhang C, Jia P, Jia Y, Li Y, Webster KA, Huang X, Achary M, Lemanski SL and Lemanski LF: Anoxia, acidosis, and intergenic interactions selectively regulate methionine sulfoxide reductase transcriptions in mouse embryonic stem cells. J Cell Biochem. 112:98–106. 2011. View Article : Google Scholar : PubMed/NCBI
26	Morel AP, Ginestier C, Pommier RM, Cabaud O, Ruiz E, Wicinski J, Devouassoux-Shisheboran M, Combaret V, Finetti P, Chassot C, et al: A stemness-related ZEB1-MSRB3 axis governs cellular pliancy and breast cancer genome stability. Nat Med. 23:568–578. 2017. View Article : Google Scholar : PubMed/NCBI
27	Hansel A, Jung S, Hoshi T and Heinemann SH: A second human methionine sulfoxide reductase (hMSRB2) reducing methionine-R-sulfoxide displays a tissue expression pattern distinct from hMSRB1. Redox Rep. 8:384–388. 2003. View Article : Google Scholar : PubMed/NCBI
28	Oakley GJ, Fuhrer K and Seethala RR: Brachyury, SOX-9, and podoplanin, new markers in the skull base chordoma vs chondrosarcoma differential: A tissue microarray-based comparative analysis. Mod Pathol. 21:1461–1469. 2008. View Article : Google Scholar : PubMed/NCBI
29	Washington K: 7th edition of the AJCC cancer staging manual: Stomach. Ann Surg Oncol. 17:3077–3079. 2010. View Article : Google Scholar : PubMed/NCBI
30	Tomczak K, Czerwińska P and Wiznerowicz M: The Cancer Genome Atlas (TCGA): An immeasurable source of knowledge. Contemp Oncol (Pozn). 19:A68–A77. 2015.PubMed/NCBI
31	Jiang YZ, Yu KD, Zuo WJ, Peng WT and Shao ZM: GATA3 mutations define a unique subtype of luminal-like breast cancer with improved survival. Cancer. 120:1329–1337. 2014. View Article : Google Scholar : PubMed/NCBI
32	Li Y, Liang L, Dai W, Cai G, Xu Y, Li X, Li Q and Cai S: Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. Mol Cancer. 15:552016. View Article : Google Scholar : PubMed/NCBI
33	Ueno H, Jones AM, Wilkinson KH, Jass JR and Talbot IC: Histological categorisation of fibrotic cancer stroma in advanced rectal cancer. Gut. 53:581–586. 2004. View Article : Google Scholar : PubMed/NCBI
34	Espejo Romero H and Navarrete Siancas J: Classification of stomach adenocarcinomas. Rev Gastroenterol Peru. 23:199–212. 2003.(In Spanish). PubMed/NCBI
35	Kwak GH, Kim JR and Kim HY: Expression, subcellular localization, and antioxidant role of mammalian methionine sulfoxide reductases in Saccharomyces cerevisiae. BMB Rep. 42:113–118. 2009. View Article : Google Scholar : PubMed/NCBI
36	Kwon TJ, Cho HJ, Kim UK, Lee E, Oh SK, Bok J, Bae YC, Yi JK, Lee JW, Ryoo ZY, et al: Methionine sulfoxide reductase B3 deficiency causes hearing loss due to stereocilia degeneration and apoptotic cell death in cochlear hair cells. Hum Mol Genet. 23:1591–1601. 2014. View Article : Google Scholar : PubMed/NCBI
37	Ahmed ZM, Yousaf R, Lee BC, Khan SN, Lee S, Lee K, Husnain T, Rehman AU, Bonneux S, Ansar M, et al: Functional null mutations of MSRB3 encoding methionine sulfoxide reductase are associated with human deafness DFNB74. Am J Hum Genet. 88:19–29. 2011. View Article : Google Scholar : PubMed/NCBI
38	Kwak GH, Kim KY and Kim HY: Methionine sulfoxide reductase B3 deficiency stimulates heme oxygenase-1 expression via ROS-dependent and Nrf2 activation pathways. Biochem Biophys Res Commun. 473:1033–1038. 2016. View Article : Google Scholar : PubMed/NCBI
39	Lee E, Kwak GH, Kamble K and Kim HY: Methionine sulfoxide reductase B3 deficiency inhibits cell growth through the activation of p53-p21 and p27 pathways. Arch Biochem Biophys. 547:1–5. 2014. View Article : Google Scholar : PubMed/NCBI
40	Ran Q, Liang H, Gu M, Qi W, Walter CA, Roberts LJ II, Herman B, Richardson A and Van Remmen H: Transgenic mice overexpressing glutathione peroxidase 4 are protected against oxidative stress-induced apoptosis. J Biol Chem. 279:55137–55146. 2004. View Article : Google Scholar : PubMed/NCBI
41	Torres M: Mitogen-activated protein kinase pathways in redox signaling. Front Biosci. 8:d369–d391. 2003. View Article : Google Scholar : PubMed/NCBI
42	Kwak GH and Kim HY: MsrB3 deficiency induces cancer cell apoptosis through p53-independent and ER stress-dependent pathways. Arch Biochem Biophys. 621:1–5. 2017. View Article : Google Scholar : PubMed/NCBI
43	Murakami D, Tsujitani S, Osaki T, Saito H, Katano K, Tatebe S and Ikeguchi M: Expression of phosphorylated Akt (pAkt) in gastric carcinoma predicts prognosis and efficacy of chemotherapy. Gastric Cancer. 10:45–51. 2007. View Article : Google Scholar : PubMed/NCBI
44	Yokota T, Ishiyama S, Saito T, Teshima S, Narushima Y, Murata K, Iwamoto K, Yashima R, Yamauchi H and Kikuchi S: Lymph node metastasis as a significant prognostic factor in gastric cancer: A multiple logistic regression analysis. Scand J Gastroenterol. 39:380–384. 2004. View Article : Google Scholar : PubMed/NCBI